Micro Cap Innovation Screener

Screening 236 names from $50M to $2B for patent activity, cash runway, revenue growth, and management quality. Includes the discovery cohort: main-universe stocks too young for a 200-week average, screened here until they earn one. 172 passed, 39 auto-rejected. Data as of 2026-09-12 10:55.

Read the 7-step methodology →

172

Passed Screening

Red Flag Rejected

Score 8+

With Patents

Ticker	Score	Patents	Runway	Rev Growth	Mkt Cap	FCF%	GM%	D/E	Insider %	Tag
KIDS OrthoPediatrics Corp.	11/12	13	CF+	+15.4%	$576.0M	0.6	74	32	31.4%	Medical Devices
Score Breakdown Patents: 3/3 • Runway: 3/3 • Revenue: 2/3 • Mgmt: 3/3 Financials Revenue: $252.7M Cash: $45.9M FCF: $3.2M ROE: -11.4% • D/E: 32% Profit Margin: -15.7% Quality FCF+ Low Debt FCF insufficient_data Patents (13) • Segmental tensioning of spinal tethers • Multiple track system for positioning of bone segments • Bone anchors with cord retention features +2 more — view all Full assessment →
XRX Xerox Holdings Corporation	11/12	554	CF+	+22.0%	$450.4M	281.7	31	778	10.1%	Industrials
Score Breakdown Patents: 3/3 • Runway: 3/3 • Revenue: 2/3 • Mgmt: 3/3 Financials Revenue: $7757.0M Cash: $495.0M FCF: $1269.0M ROE: -97.1% • D/E: 778% Profit Margin: -11.9% Quality FCF+ FCF insufficient_data Patents (554) • Characterizing meniscus behavior in 3D liquid metal printing • Display screen with icon • Printer jetting mechanism and printer employing the printer jetting mechanism +2 more — view all Full assessment →
EDIT Editas Medicine, Inc.	10/12	23	21mo	+232.3%	$414.7M	-10.7	-81	15	24.8%	Biotech
Score Breakdown Patents: 3/3 • Runway: 1/3 • Revenue: 3/3 • Mgmt: 3/3 Financials Revenue: $47.0M Cash: $211.6M FCF: $-44.3M ROE: -118.8% • D/E: 15% Profit Margin: -157.3% Quality Low Debt FCF insufficient_data Patents (23) • Systems and methods for the treatment of hemoglobinopathies • Assessing nuclease cleavage • CRISPR/Cas-related methods and compositions for treating Leber's congenital amaurosis 10 (LCA10) +2 more — view all Full assessment →
SGHT Sight Sciences, Inc.	10/12	17	41mo	+19.5%	$448.4M	-1.9	88	79	35.4%	Medical Devices
Score Breakdown Patents: 3/3 • Runway: 2/3 • Revenue: 2/3 • Mgmt: 3/3 Financials Revenue: $83.4M Cash: $79.8M FCF: $-8.6M ROE: -48.4% • D/E: 79% Profit Margin: -35.7% Quality FCF insufficient_data Patents (17) • Controller for dry eye treatment systems • Devices and methods for intraocular tissue manipulation • Ocular delivery systems and methods +2 more — view all Full assessment →
GSIT GSI Technology, Inc.	10/12	29	51mo	+0.5%	$196.4M	-4.8	53	9	14.9%	Semiconductors
Score Breakdown Patents: 3/3 • Runway: 3/3 • Revenue: 1/3 • Mgmt: 3/3 Financials Revenue: $25.2M Cash: $77.0M FCF: $-9.5M ROE: -24.5% • D/E: 9% Profit Margin: -62.9% Quality Low Debt FCF insufficient_data Patents (29) • In memory matrix multiplication and its usage in neural networks • Reference distance similarity search • Memory device for determining an extreme value +2 more — view all Full assessment →
ANGO AngioDynamics, Inc.	10/12	28	CF+	+8.0%	$631.1M	3.5	55	6	23.1%	Medical Devices
Score Breakdown Patents: 3/3 • Runway: 3/3 • Revenue: 1/3 • Mgmt: 3/3 Financials Revenue: $320.2M Cash: $53.9M FCF: $21.8M ROE: -20.8% • D/E: 6% Profit Margin: -11.5% Quality FCF+ Low Debt FCF insufficient_data Patents (28) • Multiple treatment zone ablation probe • System and method for synchronizing energy delivery to the cardiac rhythm • Systems and methods for removing undesirable material within a circulatory system +2 more — view all Full assessment →
FHTX Foghorn Therapeutics Inc.	10/12	13	24mo	+112.7%	$262.5M	-19.8	-115	-	52.7%	Biotech
Score Breakdown Patents: 3/3 • Runway: 1/3 • Revenue: 3/3 • Mgmt: 3/3 Financials Revenue: $36.7M Cash: $167.6M FCF: $-52.0M ROE: N/A • D/E: N/A Profit Margin: -175.8% Quality FCF insufficient_data Patents (13) • Compounds and uses thereof • Compounds and uses thereof • BRD9 degraders and uses thereof +2 more — view all Full assessment →
CTKB Cytek Biosciences, Inc.	10/12	11	521mo	+5.6%	$599.2M	1.6	52	8	20.8%	Medical Devices
Score Breakdown Patents: 3/3 • Runway: 3/3 • Revenue: 1/3 • Mgmt: 3/3 Financials Revenue: $206.7M Cash: $262.0M FCF: $9.3M ROE: -23.0% • D/E: 8% Profit Margin: -39.0% Quality FCF+ Low Debt FCF insufficient_data Patents (11) • Cell sorter with pivotal scuppers • Smart flow cytometers with self monitoring fluidics • Methods of forming multi-color fluorescence-based flow cytometry panel +2 more — view all Full assessment →
FDMT 4D Molecular Therapeutics, Inc.	10/12	4	28mo	+25106.7%	$727.6M	-12.5	-158	10	23.2%	Biotech
Score Breakdown Patents: 2/3 • Runway: 2/3 • Revenue: 3/3 • Mgmt: 3/3 Financials Revenue: $92.0M Cash: $361.3M FCF: $-90.8M ROE: -43.2% • D/E: 10% Profit Margin: -194.7% Quality Low Debt FCF insufficient_data Patents (4) • Adeno-associated virus variant capsids and use for inhibiting angiogenesis • Adeno-associated virus variant capsids and methods of use thereof • Adeno-associated variants, formulations and methods for pulmonary delivery +1 more — view all Full assessment →
KRMD KORU Medical Systems, Inc.	9/12	2	CF+	+18.2%	$145.9M	0.5	62	18	25.3%	Medical Devices
Score Breakdown Patents: 1/3 • Runway: 3/3 • Revenue: 2/3 • Mgmt: 3/3 Financials Revenue: $45.1M Cash: $8.3M FCF: $0.7M ROE: -10.5% • D/E: 18% Profit Margin: -4.0% Quality FCF+ Low Debt FCF insufficient_data Patents (2) • Needle insertion device • Needle insertion device Full assessment →
NNDM Nano Dimension Ltd.	9/12	15	79mo	+12.1%	$322.6M	-0.5	39	6	4.4%	Computer Hardware
Score Breakdown Patents: 3/3 • Runway: 3/3 • Revenue: 2/3 • Mgmt: 1/3 Financials Revenue: $120.9M Cash: $432.1M FCF: $-1.7M ROE: -24.5% • D/E: 6% Profit Margin: -135.2% Quality Low Debt FCF insufficient_data Patents (15) • Electromagnetic band gap element structure and fabrication methods • Systems and methods for additive manufacturing passive resistor-capacitor frequency pass filter (PRC FPF) • System and method for mimicking a neural network without access to the original training dataset or the target model +2 more — view all Red Flags SBC_HIGH (61% of revenue) Full assessment →
ALLT Allot Ltd.	9/12	3	CF+	+15.3%	$371.4M	5.3	71	6	35.1%	Enterprise Software
Score Breakdown Patents: 1/3 • Runway: 3/3 • Revenue: 2/3 • Mgmt: 3/3 Financials Revenue: $109.0M Cash: $102.2M FCF: $19.7M ROE: 9.4% • D/E: 6% Profit Margin: 9.4% Quality FCF+ Low Debt FCF insufficient_data Patents (3) • Method, system, and device of cellular traffic monitoring • System, device, and method of protecting electronic devices against fraudulent and malicious activities • System, method, and apparatus of securing and managing internet-connected devices and networks Full assessment →
RELL Richardson Electronics, Ltd.	9/12	7	CF+	+27.6%	$259.7M	-2.5	31	1	6.4%	Electronic Components
Score Breakdown Patents: 2/3 • Runway: 3/3 • Revenue: 2/3 • Mgmt: 2/3 Financials Revenue: $228.6M Cash: $31.8M FCF: $-6.5M ROE: 4.0% • D/E: 1% Profit Margin: 2.8% Quality Low Debt FCF insufficient_data Patents (7) • Hybrid capacitor energy storage • Resistor • Ultracapacitor generator start module +2 more — view all Full assessment →
AIRG Airgain, Inc.	9/12	18	33mo	+0.6%	$70.6M	-1.1	43	15	18.2%	Communication Equipment
Score Breakdown Patents: 3/3 • Runway: 2/3 • Revenue: 1/3 • Mgmt: 3/3 Financials Revenue: $51.4M Cash: $7.6M FCF: $-0.7M ROE: -23.7% • D/E: 15% Profit Margin: -13.6% Quality Low Debt FCF insufficient_data Patents (18) • Multi-band MIMO repeater system with carrier aggregation capability • Antenna assembly for a vehicle • Antenna assembly for a vehicle with sleep sense command +2 more — view all Full assessment →
ARBE Arbe Robotics Ltd.	9/12	6	12mo	+156.6%	$99.8M	-38.4	-24	64	20.4%	Scientific Instruments
Score Breakdown Patents: 2/3 • Runway: 1/3 • Revenue: 3/3 • Mgmt: 3/3 Financials Revenue: $1.9M Cash: $41.6M FCF: $-38.4M ROE: -83.2% • D/E: 64% Profit Margin: N/A Quality FCF insufficient_data Patents (6) • Method for separating targets and clutter from noise, in radar signals • Apparatus and method of two-stage signal processing in a radar system • Apparatus and method of eliminating settling time delays in a radar system +2 more — view all Full assessment →
UEIC Universal Electronics Inc.	9/12	135	CF+	-25.0%	$61.7M	26.7	30	21	23.0%	Technology
Score Breakdown Patents: 3/3 • Runway: 3/3 • Revenue: 0/3 • Mgmt: 3/3 Financials Revenue: $330.6M Cash: $32.4M FCF: $16.5M ROE: -10.2% • D/E: 21% Profit Margin: -4.6% Quality FCF+ Low Debt FCF insufficient_data Patents (135) • System and method for a self adaptive multi-user program guide • Systems and methods for a customized media access user experience with privacy settings • Controlling device configurable to enable selection of one or more services +2 more — view all Full assessment →
YEXT Yext, Inc.	9/12	24	CF+	-1.8%	$633.5M	6.6	75	622	34.1%	Enterprise Software
Score Breakdown Patents: 3/3 • Runway: 3/3 • Revenue: 0/3 • Mgmt: 3/3 Financials Revenue: $443.0M Cash: $86.8M FCF: $41.9M ROE: 27.8% • D/E: 622% Profit Margin: 5.9% Quality FCF+ High ROE Wide Moat FCF insufficient_data Patents (24) • Electronic device display or portion thereof with a graphical user interface • Online review generation using a redirection container • Online merchant review system and method utilizing dynamic URL redirection for distributing review requests +2 more — view all Full assessment →
EGHT 8x8 Inc	9/12	112	CF+	+4.9%	$265.8M	27.1	63	242	5.0%	Application Software
Score Breakdown Patents: 3/3 • Runway: 3/3 • Revenue: 1/3 • Mgmt: 2/3 Financials Revenue: $744.6M Cash: $90.6M FCF: $71.9M ROE: 3.5% • D/E: 242% Profit Margin: 0.6% Quality FCF+ FCF insufficient_data Patents (112) • Server-based service configuration system and approach • Management of VoIP device contact lists in a data communications services system • Analysis of customer interaction metrics from digital voice data in a data-communication server system +2 more — view all Full assessment →
AEYE AudioEye, Inc.	9/12	5	CF+	+8.7%	$99.7M	6.2	78	519	33.7%	Application Software
Score Breakdown Patents: 2/3 • Runway: 3/3 • Revenue: 1/3 • Mgmt: 3/3 Financials Revenue: $42.0M Cash: $8.7M FCF: $6.2M ROE: -86.7% • D/E: 519% Profit Margin: -10.9% Quality FCF+ FCF insufficient_data Patents (5) • Modular systems and methods for selectively enabling cloud-based assistive technologies • Modular systems and methods for selectively enabling cloud-based assistive technologies • Modular systems and methods for selectively enabling cloud-based assistive technologies +2 more — view all Full assessment →
BKTI BK Technologies Corporation	9/12	2	CF+	+10.6%	$273.9M	4.7	51	2	25.3%	Communication Equipment
Score Breakdown Patents: 1/3 • Runway: 3/3 • Revenue: 2/3 • Mgmt: 3/3 Financials Revenue: $90.6M Cash: $29.9M FCF: $12.9M ROE: 30.6% • D/E: 2% Profit Margin: 15.0% Quality FCF+ Low Debt High ROE Wide Moat Buffett FCF insufficient_data Patents (2) • System and method for managing access to a push-to-talk-over-cellular communication network • System and method for managing access to a push-to-talk-over-cellular communication network Full assessment →
ALDX Aldeyra Therapeutics, Inc.	9/12	15	25mo	-	$80.8M	-19.3	-	0	18.9%	Biotech
Score Breakdown Patents: 3/3 • Runway: 2/3 • Revenue: 1/3 • Mgmt: 3/3 Financials Revenue: $0.0M Cash: $45.1M FCF: $-15.6M ROE: -49.5% • D/E: 0% Profit Margin: N/A Quality Low Debt FCF insufficient_data Patents (15) • Ophthalmic formulations of methotrexate • Process for preparation of aldehyde scavenger and intermediates • Polymorphic compounds and uses thereof +2 more — view all Full assessment →
ELMD Electromed, Inc.	9/12	1	CF+	+11.6%	$228.0M	2.5	78	0	17.1%	Medical Devices
Score Breakdown Patents: 1/3 • Runway: 3/3 • Revenue: 2/3 • Mgmt: 3/3 Financials Revenue: $73.8M Cash: $20.4M FCF: $5.8M ROE: 23.3% • D/E: 0% Profit Margin: 15.3% Quality FCF+ Low Debt High ROE Wide Moat Buffett FCF insufficient_data Patents (1) • Body pulsating apparatus and method Full assessment →
RNA Atrium Therapeutics, Inc.	9/12	21	60mo	-21.9%	$177.2M	-	-56	1	11.8%	Biotech
Score Breakdown Patents: 3/3 • Runway: 3/3 • Revenue: 0/3 • Mgmt: 3/3 Financials Revenue: $35.8M Cash: $263.9M FCF: N/A ROE: N/A • D/E: 1% Profit Margin: -184.1% Quality Low Debt FCF insufficient_data Patents (21) • Compositions and methods for treating ornithine transcarbamylase deficiency • Molecules and agents for treating hepatitis B virus • Coronavirus vaccine compositions and methods +2 more — view all Full assessment →
APYX Apyx Medical Corporation	9/12	7	33mo	+22.1%	$122.2M	-7.9	64	357	27.6%	Medical Devices
Score Breakdown Patents: 2/3 • Runway: 2/3 • Revenue: 2/3 • Mgmt: 3/3 Financials Revenue: $58.4M Cash: $27.6M FCF: $-9.6M ROE: -90.7% • D/E: 357% Profit Margin: -14.8% Quality FCF insufficient_data Patents (7) • Devices, systems and methods for enhancing physiological effectiveness of medical cold plasma discharges • Electrosurgical apparatus with dynamic leakage current compensation and dynamic RF modulation • Skin status monitor and method thereof for electrosurgical apparatuses +2 more — view all Full assessment →
SMRT SmartRent, Inc.	9/12	4	CF+	+4.0%	$222.3M	2.3	36	2	11.6%	Application Software
Score Breakdown Patents: 2/3 • Runway: 3/3 • Revenue: 1/3 • Mgmt: 3/3 Financials Revenue: $151.2M Cash: $92.7M FCF: $5.1M ROE: -8.5% • D/E: 2% Profit Margin: -13.0% Quality FCF+ Low Debt FCF insufficient_data Patents (4) • Thermostat • Thermostat • Thermostat +1 more — view all Full assessment →
BWEN Broadwind, Inc.	9/12	0	CF+	+67.4%	$94.2M	16.0	12	33	13.0%	Industrial Tech
Score Breakdown Patents: 0/3 • Runway: 3/3 • Revenue: 3/3 • Mgmt: 3/3 Financials Revenue: $170.9M Cash: $17.0M FCF: $15.0M ROE: 13.1% • D/E: 33% Profit Margin: 3.2% Quality FCF+ Low Debt FCF insufficient_data Full assessment →
CAN Canaan Inc.	9/12	14	CF+	-24.3%	$251.5M	-	4	15	19.4%	Computer Hardware
Score Breakdown Patents: 3/3 • Runway: 3/3 • Revenue: 0/3 • Mgmt: 3/3 Financials Revenue: $509.7M Cash: $43.5M FCF: N/A ROE: -67.9% • D/E: 15% Profit Margin: -41.7% Quality Low Debt FCF insufficient_data Patents (14) • Cooling container for computing devices • Modular computing apparatus with integrated power and signal routing • Waste heat utilization system of immersed liquid cooling heat dissipation device +2 more — view all Full assessment →
TYGO Tigo Energy, Inc.	9/12	15	28mo	+5.6%	$77.4M	11.5	42	14	51.8%	Solar Energy
Score Breakdown Patents: 3/3 • Runway: 2/3 • Revenue: 1/3 • Mgmt: 3/3 Financials Revenue: $111.2M Cash: $16.9M FCF: $8.9M ROE: 43.1% • D/E: 14% Profit Margin: 9.0% Quality FCF+ Low Debt High ROE Wide Moat Buffett FCF insufficient_data Patents (15) • Systems and methods for remote or local shut-off of a photovoltaic system • Systems and methods for remote or local shut-off of a photovoltaic system • Synchronization of signals transmitted over power lines +2 more — view all Full assessment →
RXST RxSight, Inc.	8/12	2	110mo	+0.3%	$250.4M	-2.7	78	4	18.9%	Medical Devices
Score Breakdown Patents: 1/3 • Runway: 3/3 • Revenue: 1/3 • Mgmt: 3/3 Financials Revenue: $127.6M Cash: $208.8M FCF: $-6.7M ROE: -17.3% • D/E: 4% Profit Margin: -36.8% Quality Low Debt FCF insufficient_data Patents (2) • Light adjustable intraocular lens with a modulable absorption front protection layer • Light adjustable intraocular lens with a modulable absorption front protection layer Full assessment →
HYLN Hyliion Holdings Corp.	8/12	23	18mo	+226.3%	$696.5M	-5.8	6	2	29.7%	Consumer Cyclical
Score Breakdown Patents: 3/3 • Runway: 1/3 • Revenue: 3/3 • Mgmt: 1/3 Financials Revenue: $9.2M Cash: $64.2M FCF: $-40.2M ROE: -27.1% • D/E: 2% Profit Margin: N/A Quality Low Debt FCF insufficient_data Patents (23) • Trailer-based energy capture and management • Engine apparatus and method for operation • Drive train configurations for a vehicle with multiple reversible engines +2 more — view all Red Flags SBC_HIGH (106% of revenue) Full assessment →
QUIK QuickLogic Corporation	8/12	6	CF+	+48.7%	$198.2M	1.3	27	25	9.3%	Semiconductors
Score Breakdown Patents: 2/3 • Runway: 3/3 • Revenue: 2/3 • Mgmt: 1/3 Financials Revenue: $16.3M Cash: $18.5M FCF: $2.6M ROE: -36.2% • D/E: 25% Profit Margin: -80.1% Quality FCF+ Low Debt FCF insufficient_data Patents (6) • Programmable logic device with design for test functionality • Sectional configuration for programmable logic devices • Programmable logic device with design for test functionality +2 more — view all Red Flags SBC_HIGH (68% of revenue) Full assessment →
PUBM PubMatic, Inc.	8/12	0	CF+	+10.5%	$751.1M	8.0	64	17	10.1%	Application Software
Score Breakdown Patents: 0/3 • Runway: 3/3 • Revenue: 2/3 • Mgmt: 3/3 Financials Revenue: $289.2M Cash: $137.5M FCF: $60.3M ROE: -5.6% • D/E: 17% Profit Margin: -4.7% Quality FCF+ Low Debt FCF insufficient_data Full assessment →
POWW Outdoor Holding Company	8/12	0	CF+	+22.1%	$247.2M	4.5	88	5	16.7%	Defense & Aerospace
Score Breakdown Patents: 0/3 • Runway: 3/3 • Revenue: 2/3 • Mgmt: 3/3 Financials Revenue: $53.7M Cash: $68.8M FCF: $11.2M ROE: 2.0% • D/E: 5% Profit Margin: 12.1% Quality FCF+ Low Debt FCF insufficient_data Full assessment →
CRNC Cerence Inc.	8/12	1	CF+	+11.8%	$384.9M	18.4	79	112	2.9%	Application Software
Score Breakdown Patents: 1/3 • Runway: 3/3 • Revenue: 2/3 • Mgmt: 2/3 Financials Revenue: $309.5M Cash: $127.6M FCF: $70.7M ROE: -9.6% • D/E: 112% Profit Margin: -5.0% Quality FCF+ FCF insufficient_data Patents (1) • Voice assistant error detection system Full assessment →
AVNW Aviat Networks, Inc.	8/12	2	CF+	+4.8%	$265.4M	1.2	32	37	10.4%	Communication Equipment
Score Breakdown Patents: 1/3 • Runway: 3/3 • Revenue: 1/3 • Mgmt: 3/3 Financials Revenue: $439.7M Cash: $72.8M FCF: $3.2M ROE: 1.0% • D/E: 37% Profit Margin: 0.6% Quality FCF+ Low Debt FCF insufficient_data Patents (2) • Resilient data communications with physical layer link aggregation, extended failure detection and load balancing • Resilient data communications with physical layer link aggregation, extended failure detection and load balancing Full assessment →
WEAV Weave Communications, Inc.	8/12	0	CF+	+15.5%	$584.8M	6.7	72	60	20.3%	Health Tech
Score Breakdown Patents: 0/3 • Runway: 3/3 • Revenue: 2/3 • Mgmt: 3/3 Financials Revenue: $257.8M Cash: $78.5M FCF: $39.4M ROE: -25.1% • D/E: 60% Profit Margin: -8.0% Quality FCF+ FCF insufficient_data Full assessment →
CXDO Crexendo, Inc.	8/12	0	CF+	+48.9%	$185.4M	5.5	63	7	33.1%	Telecommunications
Score Breakdown Patents: 0/3 • Runway: 3/3 • Revenue: 2/3 • Mgmt: 3/3 Financials Revenue: $80.9M Cash: $18.3M FCF: $10.3M ROE: 6.3% • D/E: 7% Profit Margin: 5.3% Quality FCF+ Low Debt FCF insufficient_data Full assessment →
OPAL OPAL Fuels Inc.	8/12	2	CF+	+3.7%	$330.2M	-20.2	26	84	44.3%	Industrials
Score Breakdown Patents: 1/3 • Runway: 3/3 • Revenue: 1/3 • Mgmt: 3/3 Financials Revenue: $339.9M Cash: $92.5M FCF: $-66.8M ROE: 3.6% • D/E: 84% Profit Margin: 5.5% Quality FCF insufficient_data Patents (2) • Defuel priority panel • Modular and portable compressed natural gas fueling station Full assessment →
DUOT Duos Technologies Group, Inc.	8/12	0	CF+	+29.5%	$260.0M	-39.7	35	0	16.2%	Application Software
Score Breakdown Patents: 0/3 • Runway: 3/3 • Revenue: 2/3 • Mgmt: 3/3 Financials Revenue: $26.7M Cash: $112.3M FCF: $-103.1M ROE: 36.0% • D/E: 0% Profit Margin: 150.5% Quality Low Debt High ROE FCF insufficient_data Full assessment →
PRQR ProQR Therapeutics N.V.	8/12	0	29mo	+120.4%	$262.5M	-7.3	100	19	49.5%	Biotech
Score Breakdown Patents: 0/3 • Runway: 2/3 • Revenue: 3/3 • Mgmt: 3/3 Financials Revenue: $18.4M Cash: $117.1M FCF: $-19.1M ROE: -57.4% • D/E: 19% Profit Margin: -228.2% Quality Low Debt FCF insufficient_data Full assessment →
RMNI Rimini Street, Inc.	8/12	1	CF+	+6.7%	$423.8M	19.4	60	-	54.6%	Application Software
Score Breakdown Patents: 1/3 • Runway: 3/3 • Revenue: 1/3 • Mgmt: 3/3 Financials Revenue: $429.8M Cash: $124.9M FCF: $82.1M ROE: N/A • D/E: N/A Profit Margin: 1.7% Quality FCF+ FCF insufficient_data Patents (1) • Method and system for proactive client relationship analysis Full assessment →
RGNX REGENXBIO Inc.	8/12	6	5mo	+405.7%	$563.1M	-32.7	-45	349	13.3%	Biotech
Score Breakdown Patents: 2/3 • Runway: 0/3 • Revenue: 3/3 • Mgmt: 3/3 Financials Revenue: $174.5M Cash: $105.5M FCF: $-184.3M ROE: -137.6% • D/E: 349% Profit Margin: -112.6% Quality FCF insufficient_data Patents (6) • Anion exchange chromatography for recombinant AAV production • Treatment of mucopolysaccharidosis II with recombinant human iduronate-2-sulfatase (IDS) • Treatment of mucopolysaccharidosis IVA +2 more — view all Full assessment →
CGEN Compugen Ltd.	8/12	0	CF+	+107.0%	$234.0M	9.5	87	3	2.2%	Biotech
Score Breakdown Patents: 0/3 • Runway: 3/3 • Revenue: 3/3 • Mgmt: 2/3 Financials Revenue: $74.0M Cash: $125.3M FCF: $22.2M ROE: 50.6% • D/E: 3% Profit Margin: 47.6% Quality FCF+ Low Debt High ROE Wide Moat Buffett FCF insufficient_data Full assessment →
PLRX Pliant Therapeutics, Inc.	8/12	7	27mo	-	$72.4M	-58.7	-	20	11.1%	Biotech
Score Breakdown Patents: 2/3 • Runway: 2/3 • Revenue: 1/3 • Mgmt: 3/3 Financials Revenue: $0.0M Cash: $158.1M FCF: $-42.5M ROE: -50.3% • D/E: 20% Profit Margin: N/A Quality Low Debt FCF insufficient_data Patents (7) • Amino acid compounds with unbranched linkers and methods of use • Dosage forms and regimens for amino acid compounds • Substituted amino acids as integrin inhibitors +2 more — view all Full assessment →
NNBR NN, Inc.	8/12	0	CF+	+19.3%	$295.6M	6.5	15	150	17.1%	Industrials
Score Breakdown Patents: 0/3 • Runway: 3/3 • Revenue: 2/3 • Mgmt: 3/3 Financials Revenue: $455.8M Cash: $16.4M FCF: $19.1M ROE: -18.4% • D/E: 150% Profit Margin: -6.2% Quality FCF+ FCF insufficient_data Full assessment →
CLPT ClearPoint Neuro Inc.	8/12	13	12mo	+18.1%	$418.5M	-3.4	63	593	13.8%	Medical Devices
Score Breakdown Patents: 3/3 • Runway: 0/3 • Revenue: 2/3 • Mgmt: 3/3 Financials Revenue: $42.3M Cash: $29.4M FCF: $-14.1M ROE: -226.5% • D/E: 593% Profit Margin: -81.8% Quality FCF insufficient_data Patents (13) • Automatic, patient-specific targeting for deep brain stimulation • Patient-specific infusion coverage estimates using segmented 3D brain representations • Intrabody surgical fluid transfer assemblies with adjustable exposed cannula to needle tip length, related systems and methods +2 more — view all Full assessment →
AVXL Anavex Life Sciences Corp.	8/12	11	48mo	-	$242.9M	-11.1	-	-	3.1%	Biotech
Score Breakdown Patents: 3/3 • Runway: 3/3 • Revenue: 1/3 • Mgmt: 1/3 Financials Revenue: $0.0M Cash: $118.3M FCF: $-27.1M ROE: -12.8% • D/E: N/A Profit Margin: N/A Quality FCF insufficient_data Patents (11) • A19-144, A2-73 and certain anticholinesterase inhibitor compositions and method for anti-seizure therapy • Neurodevelopmental disorder therapy • Enantiomers of A2-73, analogues, and sigma agonist activity +2 more — view all Red Flags HYPE_PRICING ($0.0M rev, $243M mcap) Full assessment →
DERM Journey Medical Corporation	8/12	1	41mo	+23.3%	$204.1M	-2.7	66	80	29.8%	Pharma
Score Breakdown Patents: 1/3 • Runway: 2/3 • Revenue: 2/3 • Mgmt: 3/3 Financials Revenue: $68.2M Cash: $25.6M FCF: $-5.5M ROE: -23.8% • D/E: 80% Profit Margin: -9.0% Quality FCF insufficient_data Patents (1) • Topical tetracycline compositions Full assessment →
TMCI Treace Medical Concepts, Inc.	8/12	50	38mo	-4.2%	$293.3M	-2.1	80	108	26.4%	Medical Devices
Score Breakdown Patents: 3/3 • Runway: 2/3 • Revenue: 0/3 • Mgmt: 3/3 Financials Revenue: $205.3M Cash: $45.6M FCF: $-6.3M ROE: -72.0% • D/E: 108% Profit Margin: -29.0% Quality FCF insufficient_data Patents (50) • Cut guide with integrated joint realignment features • Contoured bone plate with locking screw for bone compression, particularly across a tarsometatarsal joint • Bone positioning and preparing guide systems and methods +2 more — view all Full assessment →
PLBY Playboy, Inc.	8/12	0	CF+	+10.9%	$136.6M	7.4	73	849	42.9%	Consumer Cyclical
Score Breakdown Patents: 0/3 • Runway: 3/3 • Revenue: 2/3 • Mgmt: 3/3 Financials Revenue: $125.4M Cash: $31.9M FCF: $10.1M ROE: 2.4% • D/E: 849% Profit Margin: 0.2% Quality FCF+ FCF insufficient_data Full assessment →
MNOV MediciNova, Inc.	8/12	8	34mo	+240.6%	$89.1M	-6.4	38	0	14.2%	Biotech
Score Breakdown Patents: 2/3 • Runway: 2/3 • Revenue: 3/3 • Mgmt: 1/3 Financials Revenue: $0.9M Cash: $25.4M FCF: $-5.7M ROE: -25.6% • D/E: 0% Profit Margin: N/A Quality Low Debt FCF insufficient_data Patents (8) • Methods of treating post-COVID condition(s) • Treatment of progressive neurodegenerative disease with ibudilast • Methods of reducing plasma level of macrophage migratory inhibitory factor in patients +2 more — view all Red Flags SBC_HIGH (178% of revenue) Full assessment →
CURV Torrid Holdings Inc.	8/12	5	390mo	-11.8%	$224.4M	9.8	34	-	73.9%	Consumer Cyclical
Score Breakdown Patents: 2/3 • Runway: 3/3 • Revenue: 0/3 • Mgmt: 3/3 Financials Revenue: $948.8M Cash: $22.0M FCF: $21.9M ROE: N/A • D/E: N/A Profit Margin: -0.9% Quality FCF+ FCF insufficient_data Patents (5) • Wire-free push-up brassiere with hinge for improved support and flexibility • Power mesh panels for tummy-covering garments • Wire-free push-up brassiere with hinge for improved support and flexibility +2 more — view all Full assessment →
CURI CuriosityStream Inc.	8/12	0	CF+	+22.3%	$157.8M	19.1	63	9	31.6%	Communication Services
Score Breakdown Patents: 0/3 • Runway: 3/3 • Revenue: 2/3 • Mgmt: 3/3 Financials Revenue: $76.0M Cash: $6.9M FCF: $30.1M ROE: 0.1% • D/E: 9% Profit Margin: N/A Quality FCF+ Low Debt FCF insufficient_data Full assessment →
BRLT Brilliant Earth Group, Inc.	8/12	2	CF+	+5.7%	$144.6M	3.4	56	57	10.2%	Consumer Cyclical
Score Breakdown Patents: 1/3 • Runway: 3/3 • Revenue: 1/3 • Mgmt: 3/3 Financials Revenue: $449.3M Cash: $74.9M FCF: $4.9M ROE: -10.9% • D/E: 57% Profit Margin: -1.0% Quality FCF+ FCF insufficient_data Patents (2) • Ring • Bracelet Full assessment →
ALTO Alto Ingredients, Inc.	8/12	0	CF+	+12.5%	$302.5M	7.5	7	32	10.7%	Basic Materials
Score Breakdown Patents: 0/3 • Runway: 3/3 • Revenue: 2/3 • Mgmt: 3/3 Financials Revenue: $943.3M Cash: $24.0M FCF: $22.6M ROE: 22.2% • D/E: 32% Profit Margin: 5.5% Quality FCF+ Low Debt High ROE Buffett FCF insufficient_data Full assessment →
FATN FatPipe, Inc.	8/12	0	54mo	+27.8%	$79.3M	-0.5	91	21	43.4%	Enterprise Software
Score Breakdown Patents: 0/3 • Runway: 3/3 • Revenue: 2/3 • Mgmt: 3/3 Financials Revenue: $20.3M Cash: $4.3M FCF: $-0.4M ROE: 23.3% • D/E: 21% Profit Margin: 26.8% Quality Low Debt High ROE Wide Moat FCF insufficient_data Full assessment →
PERF Perfect Corp.	8/12	1	CF+	-	$196.6M	2.8	80	0	62.7%	Application Software
Score Breakdown Patents: 1/3 • Runway: 3/3 • Revenue: 1/3 • Mgmt: 3/3 Financials Revenue: $71.1M Cash: $162.0M FCF: $5.5M ROE: 3.8% • D/E: 0% Profit Margin: 8.1% Quality FCF+ Low Debt FCF insufficient_data Patents (1) • Blender including an integrated smart scale and a recipe application Full assessment →
NEXN Nexxen International Ltd.	8/12	0	CF+	+10.5%	$521.7M	11.7	82	8	14.5%	Communication Services
Score Breakdown Patents: 0/3 • Runway: 3/3 • Revenue: 2/3 • Mgmt: 3/3 Financials Revenue: $382.9M Cash: $132.0M FCF: $61.0M ROE: 2.7% • D/E: 8% Profit Margin: 3.4% Quality FCF+ Low Debt FCF insufficient_data Full assessment →
SMC Summit Midstream Corporation	8/12	0	CF+	+10.6%	$469.3M	-0.8	45	135	77.2%	Energy
Score Breakdown Patents: 0/3 • Runway: 3/3 • Revenue: 2/3 • Mgmt: 3/3 Financials Revenue: $584.3M Cash: $21.0M FCF: $-3.6M ROE: -2.9% • D/E: 135% Profit Margin: -3.5% Quality FCF insufficient_data Full assessment →
OVID Ovid Therapeutics Inc.	8/12	12	26mo	-88.3%	$525.4M	-6.3	100	6	16.3%	Biotech
Score Breakdown Patents: 3/3 • Runway: 2/3 • Revenue: 0/3 • Mgmt: 3/3 Financials Revenue: $1.6M Cash: $117.2M FCF: $-33.1M ROE: -26.0% • D/E: 6% Profit Margin: N/A Quality Low Debt FCF insufficient_data Patents (12) • Use of (s)-3-amino-4-(difluoromethylenyl) cyclopent-1-ene-1-carboxylic acid and related compounds, (1S,3S)-3-amino-4-(difluoromethylidene) cyclopentane-1-carboxylic acid and vigabatrin in the treatment of developmental disorders • Methods of treating developmental disorders with gaboxadol • Use of (S)-3-amino-4-(difluoromethylenyl) cyclopent-1-ene-1-carboxylic acid and related compounds, (1S,3S)-3-amino-4-(difluoromethylidene) cyclopentane-1-carboxylic acid and vigabatrin in the treatment of developmental disorders +2 more — view all Full assessment →
ELMT The Elmet Group Co.	8/12	0	269mo	+35.2%	$493.1M	-	23	12	66.8%	Defense & Aerospace
Score Breakdown Patents: 0/3 • Runway: 3/3 • Revenue: 2/3 • Mgmt: 3/3 Financials Revenue: $228.5M Cash: $71.0M FCF: N/A ROE: N/A • D/E: 12% Profit Margin: -1.3% Quality Low Debt FCF insufficient_data Full assessment →
RNGR Ranger Energy Services, Inc.	8/12	0	CF+	+25.5%	$406.0M	-1.7	18	16	21.7%	Energy Services
Score Breakdown Patents: 0/3 • Runway: 3/3 • Revenue: 2/3 • Mgmt: 3/3 Financials Revenue: $606.7M Cash: $4.2M FCF: $-6.8M ROE: 4.9% • D/E: 16% Profit Margin: 2.4% Quality Low Debt FCF insufficient_data Full assessment →
LAB Standard BioTools Inc.	8/12	4	71mo	-7.6%	$270.9M	65.2	50	5	53.0%	Medical Devices
Score Breakdown Patents: 2/3 • Runway: 3/3 • Revenue: 0/3 • Mgmt: 3/3 Financials Revenue: $84.6M Cash: $476.7M FCF: $176.6M ROE: -11.2% • D/E: 5% Profit Margin: 100.4% Quality FCF+ Low Debt FCF insufficient_data Patents (4) • Scientific instrument • Parallelized sample processing and library prep • Parallelized sample processing and library prep +1 more — view all Full assessment →
SHIP Seanergy Maritime Holdings Corp	8/12	0	CF+	+48.6%	$398.9M	2.2	68	94	31.1%	Industrials
Score Breakdown Patents: 0/3 • Runway: 3/3 • Revenue: 2/3 • Mgmt: 3/3 Financials Revenue: $194.2M Cash: $48.1M FCF: $8.7M ROE: 21.4% • D/E: 94% Profit Margin: 31.5% Quality FCF+ High ROE Wide Moat FCF insufficient_data Full assessment →
PROF Profound Medical Corp.	7/12	8	13mo	+12.3%	$218.1M	-11.4	72	15	2.8%	Medical Devices
Score Breakdown Patents: 2/3 • Runway: 1/3 • Revenue: 2/3 • Mgmt: 2/3 Financials Revenue: $19.1M Cash: $38.3M FCF: $-24.8M ROE: -73.5% • D/E: 15% Profit Margin: -171.6% Quality Low Debt FCF insufficient_data Patents (8) • Multi-channel real-time phase modulation for EMI reduction in an ultrasound device • System and method for open-loop ultrasound therapy to the prostate including restricting the therapy delivered to a predetermined angular range • Ultrasonic therapy applicator and method of determining position of ultrasound transducers +2 more — view all Full assessment →
EGAN eGain Corporation	7/12	1	CF+	-4.7%	$137.7M	-	73	3	47.4%	Application Software
Score Breakdown Patents: 1/3 • Runway: 3/3 • Revenue: 0/3 • Mgmt: 3/3 Financials Revenue: $91.1M Cash: $73.3M FCF: N/A ROE: 10.8% • D/E: 3% Profit Margin: 9.7% Quality Low Debt FCF insufficient_data Patents (1) • System and method for automatic agent assistance based on real-time metrics Full assessment →
OSPN OneSpan Inc.	7/12	2	CF+	+1.0%	$624.7M	5.2	74	4	2.6%	Enterprise Software
Score Breakdown Patents: 1/3 • Runway: 3/3 • Revenue: 1/3 • Mgmt: 2/3 Financials Revenue: $246.4M Cash: $43.3M FCF: $32.7M ROE: 26.5% • D/E: 4% Profit Margin: 27.8% Quality FCF+ Low Debt High ROE Wide Moat Buffett FCF insufficient_data Patents (2) • Blockchain-enhanced proof of identity • Blockchain-enhanced proof of identity Full assessment →
PSFE Paysafe Limited	7/12	0	CF+	+4.5%	$331.0M	57.9	56	447	53.0%	Enterprise Software
Score Breakdown Patents: 0/3 • Runway: 3/3 • Revenue: 1/3 • Mgmt: 3/3 Financials Revenue: $1762.3M Cash: $226.2M FCF: $191.8M ROE: -30.3% • D/E: 447% Profit Margin: -11.8% Quality FCF+ FCF insufficient_data Full assessment →
PACB Pacific Biosciences of Californ	7/12	59	24mo	-1.9%	$404.1M	72.2	29	-	2.2%	Medical Devices
Score Breakdown Patents: 3/3 • Runway: 2/3 • Revenue: 0/3 • Mgmt: 2/3 Financials Revenue: $159.3M Cash: $236.9M FCF: $291.6M ROE: -929.3% • D/E: N/A Profit Margin: -82.5% Quality FCF+ FCF insufficient_data Patents (59) • Methods and compositions for sequencing double stranded nucleic acids • Protected dye-labeled reagents • High speed scanning system with acceleration tracking +2 more — view all Full assessment →
TATT TAT Technologies Ltd.	7/12	0	CF+	+22.8%	$499.9M	0.2	25	9	0.5%	Defense & Aerospace
Score Breakdown Patents: 0/3 • Runway: 3/3 • Revenue: 2/3 • Mgmt: 2/3 Financials Revenue: $186.9M Cash: $54.6M FCF: $0.9M ROE: 11.9% • D/E: 9% Profit Margin: 11.3% Quality FCF+ Low Debt FCF insufficient_data Full assessment →
WRAP Wrap Technologies, Inc.	7/12	13	6mo	+102.8%	$103.8M	-4.2	64	3	34.4%	Scientific Instruments
Score Breakdown Patents: 3/3 • Runway: 0/3 • Revenue: 3/3 • Mgmt: 1/3 Financials Revenue: $6.1M Cash: $4.8M FCF: $-4.4M ROE: -107.7% • D/E: 3% Profit Margin: -223.1% Quality Low Debt FCF insufficient_data Patents (13) • Projectile cassette • Systems and methods for generating optical beam arrays • Projectile anchor +2 more — view all Red Flags SBC_HIGH (91% of revenue) Full assessment →
INVZ Innoviz Technologies Ltd.	7/12	22	11mo	+85.5%	$93.0M	-25.1	6	73	26.9%	Consumer Cyclical
Score Breakdown Patents: 3/3 • Runway: 0/3 • Revenue: 3/3 • Mgmt: 1/3 Financials Revenue: $53.2M Cash: $48.4M FCF: $-23.3M ROE: -114.8% • D/E: 73% Profit Margin: -153.1% Quality FCF insufficient_data Patents (22) • Systems and methods for photodiode-based detection • Efficient optical transmission in LIDAR systems • Distributing LIDAR system components +2 more — view all Red Flags SBC_HIGH (56% of revenue) Full assessment →
LUNG Pulmonx Corporation	7/12	18	22mo	-4.6%	$78.1M	-15.0	77	143	11.0%	Medical Devices
Score Breakdown Patents: 3/3 • Runway: 1/3 • Revenue: 0/3 • Mgmt: 3/3 Financials Revenue: $87.4M Cash: $55.8M FCF: $-11.7M ROE: -88.9% • D/E: 143% Profit Margin: -55.0% Quality FCF insufficient_data Patents (18) • Devices and systems for lung treatment • Methods and systems for endobronchial diagnostics • Methods, systems, and devices for analyzing lung imaging data +2 more — view all Full assessment →
SSTI SoundThinking, Inc.	7/12	1	CF+	-7.7%	$73.8M	9.0	51	8	45.7%	Application Software
Score Breakdown Patents: 1/3 • Runway: 3/3 • Revenue: 0/3 • Mgmt: 3/3 Financials Revenue: $98.0M Cash: $6.5M FCF: $6.6M ROE: -23.7% • D/E: 8% Profit Margin: -16.9% Quality FCF+ Low Debt FCF insufficient_data Patents (1) • Systems and methods for weapon and destructive device detection based on electromagnetic field profile Full assessment →
CODA Coda Octopus Group, Inc.	7/12	3	CF+	-1.6%	$113.0M	3.8	67	1	49.1%	Defense & Aerospace
Score Breakdown Patents: 1/3 • Runway: 3/3 • Revenue: 0/3 • Mgmt: 3/3 Financials Revenue: $28.0M Cash: $30.7M FCF: $4.3M ROE: 8.4% • D/E: 1% Profit Margin: 17.7% Quality FCF+ Low Debt FCF insufficient_data Patents (3) • Technologies for dynamic, real-time, four-dimensional volumetric multi-object underwater scene segmentation • Method of stabilizing sonar images • Combined method of location of sonar detection device Full assessment →
BLZE Backblaze, Inc.	7/12	0	CF+	+17.7%	$767.6M	4.4	62	93	4.1%	Enterprise Software
Score Breakdown Patents: 0/3 • Runway: 3/3 • Revenue: 2/3 • Mgmt: 2/3 Financials Revenue: $156.3M Cash: $49.9M FCF: $33.5M ROE: -24.3% • D/E: 93% Profit Margin: -13.1% Quality FCF+ FCF insufficient_data Full assessment →
RBBN Ribbon Communications Inc.	7/12	1	CF+	-12.8%	$355.9M	11.2	51	101	48.3%	Application Software
Score Breakdown Patents: 1/3 • Runway: 3/3 • Revenue: 0/3 • Mgmt: 3/3 Financials Revenue: $797.6M Cash: $43.5M FCF: $39.8M ROE: 4.1% • D/E: 101% Profit Margin: 2.0% Quality FCF+ FCF insufficient_data Patents (1) • Telecommunication call emulation Full assessment →
SMWB Similarweb Ltd.	7/12	0	CF+	+8.8%	$712.2M	4.1	80	201	52.5%	Application Software
Score Breakdown Patents: 0/3 • Runway: 3/3 • Revenue: 1/3 • Mgmt: 3/3 Financials Revenue: $295.6M Cash: $73.9M FCF: $29.1M ROE: -94.0% • D/E: 201% Profit Margin: -7.4% Quality FCF+ FCF insufficient_data Full assessment →
SIGA SIGA Technologies Inc.	7/12	3	70mo	-49.5%	$217.7M	-11.0	16	0	42.8%	Pharma
Score Breakdown Patents: 1/3 • Runway: 3/3 • Revenue: 0/3 • Mgmt: 3/3 Financials Revenue: $53.7M Cash: $117.6M FCF: $-24.0M ROE: -1.5% • D/E: 0% Profit Margin: -5.2% Quality Low Debt FCF insufficient_data Patents (3) • Polymorphic forms of ST-246 and methods of preparation • ST-246 (tecovirimat monohydrate) suspension formulations • Polymorphic forms of ST-246 and methods of preparation Full assessment →
GDYN Grid Dynamics Holdings, Inc.	7/12	0	CF+	+7.0%	$647.4M	3.5	35	3	31.0%	IT Services
Score Breakdown Patents: 0/3 • Runway: 3/3 • Revenue: 1/3 • Mgmt: 3/3 Financials Revenue: $422.6M Cash: $298.4M FCF: $22.7M ROE: 0.5% • D/E: 3% Profit Margin: 0.7% Quality FCF+ Low Debt FCF insufficient_data Full assessment →
FLGT Fulgent Genetics, Inc.	7/12	1	37mo	+4.4%	$562.7M	-16.2	36	1	39.3%	Diagnostics
Score Breakdown Patents: 1/3 • Runway: 2/3 • Revenue: 1/3 • Mgmt: 3/3 Financials Revenue: $323.9M Cash: $257.0M FCF: $-90.9M ROE: -8.1% • D/E: 1% Profit Margin: -26.0% Quality Low Debt FCF insufficient_data Patents (1) • Nanoparticles containing a taxane and their use Full assessment →
EOLS Evolus, Inc. Common Stock	7/12	0	35mo	+21.2%	$517.8M	-0.3	66	-	27.9%	Pharma
Score Breakdown Patents: 0/3 • Runway: 2/3 • Revenue: 2/3 • Mgmt: 3/3 Financials Revenue: $316.5M Cash: $45.2M FCF: $-1.8M ROE: N/A • D/E: N/A Profit Margin: -10.8% Quality FCF insufficient_data Full assessment →
AUTL Autolus Therapeutics plc	7/12	0	CF+	-	$500.4M	-	-	-	87.3%	Biotech
Score Breakdown Patents: 0/3 • Runway: 3/3 • Revenue: 1/3 • Mgmt: 3/3 Financials Revenue: $1.1M Cash: $217.4M FCF: N/A ROE: -29.6% • D/E: N/A Profit Margin: N/A Quality FCF insufficient_data Full assessment →
ORMP Oramed Pharmaceuticals Inc.	7/12	0	117mo	-	$190.7M	1.3	-	0	22.4%	Biotech
Score Breakdown Patents: 0/3 • Runway: 3/3 • Revenue: 1/3 • Mgmt: 3/3 Financials Revenue: $0.0M Cash: $50.6M FCF: $2.5M ROE: 74.2% • D/E: 0% Profit Margin: N/A Quality FCF+ Low Debt High ROE FCF insufficient_data Full assessment →
MYPS PLAYSTUDIOS, Inc.	7/12	2	CF+	-7.3%	$59.0M	46.5	78	3	20.2%	Communication Services
Score Breakdown Patents: 1/3 • Runway: 3/3 • Revenue: 0/3 • Mgmt: 3/3 Financials Revenue: $226.5M Cash: $102.7M FCF: $27.4M ROE: -20.6% • D/E: 3% Profit Margin: -20.6% Quality FCF+ Low Debt FCF insufficient_data Patents (2) • Method, system, and apparatus for enabling players to earn tangible rewards on a social game • Cash slot machine augmented with secondary currency Full assessment →
STTK Shattuck Labs, Inc.	7/12	9	61mo	-	$622.3M	-3.4	-	1	32.5%	Biotech
Score Breakdown Patents: 2/3 • Runway: 3/3 • Revenue: 1/3 • Mgmt: 1/3 Financials Revenue: $1.0M Cash: $208.3M FCF: $-21.2M ROE: -39.2% • D/E: 1% Profit Margin: N/A Quality Low Debt FCF insufficient_data Patents (9) • Heterodimeric proteins and uses thereof • Fusion proteins for the treatment of cardiometabolic diseases • Antibodies that bind TNFRSF25 +2 more — view all Red Flags SBC_HIGH (1154% of revenue) Full assessment →
ZVIA Zevia PBC	7/12	0	CF+	+1.1%	$90.9M	9.6	48	1	31.3%	Consumer Defensive
Score Breakdown Patents: 0/3 • Runway: 3/3 • Revenue: 1/3 • Mgmt: 3/3 Financials Revenue: $169.8M Cash: $28.5M FCF: $8.7M ROE: -26.5% • D/E: 1% Profit Margin: -5.3% Quality FCF+ Low Debt FCF insufficient_data Full assessment →
XBIT XBiotech Inc.	7/12	3	32mo	-	$66.8M	-42.7	-	-	25.1%	Biotech
Score Breakdown Patents: 1/3 • Runway: 2/3 • Revenue: 1/3 • Mgmt: 3/3 Financials Revenue: $0.0M Cash: $109.5M FCF: $-28.5M ROE: -29.9% • D/E: N/A Profit Margin: N/A Quality FCF insufficient_data Patents (3) • Arthritis treatment • Compositions and methods for treating and preventing Staphylococcus aureus infections • Treatment for neoplastic diseases Full assessment →
ASUR Asure Software Inc	7/12	0	CF+	+23.2%	$244.0M	2.2	68	38	8.9%	Application Software
Score Breakdown Patents: 0/3 • Runway: 3/3 • Revenue: 2/3 • Mgmt: 2/3 Financials Revenue: $155.4M Cash: $19.7M FCF: $5.5M ROE: -4.3% • D/E: 38% Profit Margin: -5.4% Quality FCF+ Low Debt FCF insufficient_data Full assessment →
HOVR New Horizon Aircraft Ltd.	7/12	0	57mo	-	$110.9M	-8.9	-	0	19.0%	Defense & Aerospace
Score Breakdown Patents: 0/3 • Runway: 3/3 • Revenue: 1/3 • Mgmt: 3/3 Financials Revenue: $0.0M Cash: $78.3M FCF: $-9.8M ROE: -89.8% • D/E: 0% Profit Margin: N/A Quality Low Debt FCF insufficient_data Full assessment →
SUPX SuperX AI Technology Limited	7/12	0	53mo	+283.8%	$334.7M	-4.6	12	1	29.3%	Enterprise Software
Score Breakdown Patents: 0/3 • Runway: 3/3 • Revenue: 3/3 • Mgmt: 1/3 Financials Revenue: $5.7M Cash: $188.1M FCF: $-15.3M ROE: -85.6% • D/E: 1% Profit Margin: N/A Quality Low Debt FCF insufficient_data Red Flags SBC_HIGH (854% of revenue) Full assessment →
SES SES AI Corporation	7/12	0	34mo	+43.8%	$196.9M	-14.3	28	4	12.4%	Consumer Cyclical
Score Breakdown Patents: 0/3 • Runway: 2/3 • Revenue: 2/3 • Mgmt: 3/3 Financials Revenue: $23.5M Cash: $163.0M FCF: $-28.2M ROE: -31.2% • D/E: 4% Profit Margin: -289.6% Quality Low Debt FCF insufficient_data Full assessment →
FATE Fate Therapeutics, Inc.	6/12	18	18mo	+9.2%	$276.8M	-17.6	-	49	12.2%	Biotech
Score Breakdown Patents: 3/3 • Runway: 1/3 • Revenue: 1/3 • Mgmt: 1/3 Financials Revenue: $6.5M Cash: $153.8M FCF: $-48.7M ROE: -60.8% • D/E: 49% Profit Margin: N/A Quality Low Debt FCF insufficient_data Patents (18) • Combining iPSC derived effector cell types for immunotherapy use • Vial rack • Cell culture platform for single cell sorting and enhanced reprogramming of iPSCs +2 more — view all Red Flags SBC_HIGH (371% of revenue) Full assessment →
MDXH MDxHealth SA	6/12	0	44mo	+2.3%	$67.2M	-25.9	63	-	55.4%	Diagnostics
Score Breakdown Patents: 0/3 • Runway: 2/3 • Revenue: 1/3 • Mgmt: 3/3 Financials Revenue: $114.0M Cash: $19.2M FCF: $-17.4M ROE: N/A • D/E: N/A Profit Margin: -32.7% Quality FCF insufficient_data Full assessment →
MASS 908 Devices Inc.	6/12	0	CF+	+23.3%	$393.5M	4.8	53	3	32.1%	Medical Devices
Score Breakdown Patents: 0/3 • Runway: 3/3 • Revenue: 2/3 • Mgmt: 1/3 Financials Revenue: $60.8M Cash: $101.5M FCF: $18.7M ROE: -25.0% • D/E: 3% Profit Margin: -57.0% Quality FCF+ Low Debt FCF insufficient_data Red Flags SBC_HIGH (59% of revenue) Full assessment →
AIRS AirSculpt Technologies, Inc.	6/12	0	CF+	-2.5%	$174.5M	4.6	66	67	76.7%	Healthcare
Score Breakdown Patents: 0/3 • Runway: 3/3 • Revenue: 0/3 • Mgmt: 3/3 Financials Revenue: $150.7M Cash: $18.8M FCF: $8.0M ROE: -12.0% • D/E: 67% Profit Margin: -7.8% Quality FCF+ FCF insufficient_data Full assessment →
SPWR SunPower Inc.	6/12	21	1mo	-17.0%	$70.3M	5.5	52	-	35.6%	Solar Energy
Score Breakdown Patents: 3/3 • Runway: 0/3 • Revenue: 0/3 • Mgmt: 3/3 Financials Revenue: $283.1M Cash: $4.1M FCF: $3.9M ROE: N/A • D/E: N/A Profit Margin: -3.8% Quality FCF+ FCF insufficient_data Patents (21) • Water sealing surface attachment • Systems and method for determining solar panel placement and energy output • Methods of recycling silicon swarf into electronic grade polysilicon or metallurgical-grade silicon +2 more — view all Full assessment →
AIOT PowerFleet, Inc.	6/12	0	CF+	+6.4%	$402.7M	6.4	56	60	7.6%	Application Software
Score Breakdown Patents: 0/3 • Runway: 3/3 • Revenue: 1/3 • Mgmt: 2/3 Financials Revenue: $450.4M Cash: $32.8M FCF: $25.8M ROE: -3.8% • D/E: 60% Profit Margin: -4.2% Quality FCF+ FCF insufficient_data Full assessment →
HYPR Hyperfine, Inc.	6/12	1	19mo	+44.8%	$83.8M	-20.5	51	36	5.0%	Medical Devices
Score Breakdown Patents: 1/3 • Runway: 1/3 • Revenue: 2/3 • Mgmt: 2/3 Financials Revenue: $16.5M Cash: $43.5M FCF: $-17.2M ROE: -97.0% • D/E: 36% Profit Margin: -210.8% Quality Low Debt FCF insufficient_data Patents (1) • Suppressing image artifact with RF pulse phase in multi-shot SS-FSE sequence Full assessment →
KORE KORE Group Holdings, Inc.	6/12	0	CF+	-8.8%	$163.0M	17.7	56	-	60.8%	Telecommunications
Score Breakdown Patents: 0/3 • Runway: 3/3 • Revenue: 0/3 • Mgmt: 3/3 Financials Revenue: $279.6M Cash: $28.9M FCF: $28.8M ROE: N/A • D/E: N/A Profit Margin: -27.4% Quality FCF+ FCF insufficient_data Full assessment →
MAPS WM Technology, Inc.	6/12	0	CF+	-5.4%	$62.2M	15.3	95	18	15.4%	Application Software
Score Breakdown Patents: 0/3 • Runway: 3/3 • Revenue: 0/3 • Mgmt: 3/3 Financials Revenue: $171.2M Cash: $60.5M FCF: $9.5M ROE: 2.4% • D/E: 18% Profit Margin: 1.2% Quality FCF+ Low Debt FCF insufficient_data Full assessment →
TTGT TechTarget, Inc.	6/12	0	CF+	-3.2%	$279.9M	14.2	59	26	70.8%	IT Services
Score Breakdown Patents: 0/3 • Runway: 3/3 • Revenue: 0/3 • Mgmt: 3/3 Financials Revenue: $485.2M Cash: $45.8M FCF: $39.7M ROE: -30.4% • D/E: 26% Profit Margin: -36.8% Quality FCF+ Low Debt FCF insufficient_data Full assessment →
DOMO Domo, Inc.	6/12	0	504mo	-3.7%	$180.1M	6.0	75	-	16.0%	Application Software
Score Breakdown Patents: 0/3 • Runway: 3/3 • Revenue: 0/3 • Mgmt: 3/3 Financials Revenue: $315.2M Cash: $25.1M FCF: $10.9M ROE: N/A • D/E: N/A Profit Margin: -13.4% Quality FCF+ FCF insufficient_data Full assessment →
XNET Xunlei Limited	6/12	0	CF+	-1.4%	$312.3M	-	50	6	55.0%	Enterprise Software
Score Breakdown Patents: 0/3 • Runway: 3/3 • Revenue: 0/3 • Mgmt: 3/3 Financials Revenue: $493.4M Cash: $276.9M FCF: N/A ROE: -8.9% • D/E: 6% Profit Margin: -14.5% Quality Low Debt FCF insufficient_data Full assessment →
GEVO Gevo, Inc.	6/12	6	43mo	+7.1%	$388.2M	4.8	45	61	8.0%	Basic Materials
Score Breakdown Patents: 2/3 • Runway: 2/3 • Revenue: 1/3 • Mgmt: 1/3 Financials Revenue: $177.5M Cash: $58.1M FCF: $18.5M ROE: -55.5% • D/E: 61% Profit Margin: -119.9% Quality FCF+ FCF insufficient_data Patents (6) • Selective formation of jet and diesel fuels from bio-based C3-C8 olefins via oligomerization with tungstated catalysts • Simultaneous dehydration, dimerization, and metathesis of C2-C5 alcohols • Upgrading of fusel oils over doped alumina +2 more — view all Red Flags SBC_HIGH (111% of revenue) Full assessment →
BLNK Blink Charging Co.	6/12	1	72mo	-24.5%	$78.9M	23.8	34	9	1.5%	Industrials
Score Breakdown Patents: 1/3 • Runway: 3/3 • Revenue: 0/3 • Mgmt: 2/3 Financials Revenue: $96.5M Cash: $34.0M FCF: $18.8M ROE: -85.5% • D/E: 9% Profit Margin: -52.5% Quality FCF+ Low Debt FCF insufficient_data Patents (1) • Self-aligning holster for J1772 plug used in electric vehicle supply equipment Full assessment →
INFU InfuSystems Holdings, Inc.	6/12	0	CF+	+2.6%	$245.2M	4.2	58	42	7.1%	Medical Devices
Score Breakdown Patents: 0/3 • Runway: 3/3 • Revenue: 1/3 • Mgmt: 2/3 Financials Revenue: $143.3M Cash: $1.0M FCF: $10.3M ROE: 15.0% • D/E: 42% Profit Margin: 6.0% Quality FCF+ Low Debt FCF insufficient_data Full assessment →
MBOT Microbot Medical Inc.	6/12	2	46mo	-	$97.4M	-14.6	-185	1	0.0%	Medical Devices
Score Breakdown Patents: 1/3 • Runway: 2/3 • Revenue: 1/3 • Mgmt: 2/3 Financials Revenue: $0.3M Cash: $67.4M FCF: $-14.2M ROE: -32.9% • D/E: 1% Profit Margin: N/A Quality Low Debt FCF insufficient_data Patents (2) • Modular robotic system for driving movement of surgical tools • Device for automatically inserting and manipulating a medical tool into and within a bodily lumen Full assessment →
IMMP Immutep Limited	6/12	1	15mo	+633.5%	$55.0M	-67.2	-	2	2.9%	Biotech
Score Breakdown Patents: 1/3 • Runway: 1/3 • Revenue: 3/3 • Mgmt: 1/3 Financials Revenue: $19.9M Cash: $68.9M FCF: $-37.0M ROE: -77.3% • D/E: 2% Profit Margin: N/A Quality Low Debt FCF insufficient_data Patents (1) • Device for cutting, separation, and discharge of syringe Red Flags SBC_HIGH (120% of revenue) Full assessment →
IPHA Innate Pharma S.A.	6/12	16	8mo	-46.7%	$208.9M	-16.3	-	-	36.8%	Biotech
Score Breakdown Patents: 3/3 • Runway: 0/3 • Revenue: 0/3 • Mgmt: 3/3 Financials Revenue: $9.0M Cash: $34.3M FCF: $-34.1M ROE: N/A • D/E: N/A Profit Margin: N/A Quality FCF insufficient_data Patents (16) • Variable regions for NKp46 binding proteins • Treatment of peripheral T cell lymphoma • NKp46 binding agents +2 more — view all Full assessment →
HUMA Humacyte, Inc.	6/12	4	10mo	+34.9%	$157.7M	-37.0	-	214	9.6%	Biotech
Score Breakdown Patents: 2/3 • Runway: 0/3 • Revenue: 2/3 • Mgmt: 2/3 Financials Revenue: $2.1M Cash: $79.9M FCF: $-58.4M ROE: -547.9% • D/E: 214% Profit Margin: N/A Quality FCF insufficient_data Patents (4) • Fluid systems, apparatuses, devices and methods of management thereof for cultivating tissue • Tubular prostheses • Drawer system for cultivating tissue +1 more — view all Full assessment →
RPAY Repay Holdings Corporation	6/12	0	CF+	+33.2%	$313.9M	19.5	74	165	49.0%	Enterprise Software
Score Breakdown Patents: 0/3 • Runway: 3/3 • Revenue: 2/3 • Mgmt: 1/3 Financials Revenue: $337.8M Cash: $83.7M FCF: $61.3M ROE: -31.8% • D/E: 165% Profit Margin: -49.6% Quality FCF+ FCF insufficient_data Red Flags SBC_HIGH (83% of revenue) Full assessment →
FULC Fulcrum Therapeutics, Inc.	6/12	2	58mo	-	$289.9M	-12.9	-	2	16.8%	Biotech
Score Breakdown Patents: 1/3 • Runway: 3/3 • Revenue: 1/3 • Mgmt: 1/3 Financials Revenue: $0.0M Cash: $318.8M FCF: $-37.4M ROE: -32.4% • D/E: 2% Profit Margin: N/A Quality Low Debt FCF insufficient_data Patents (2) • Compositions and methods for modulating FMR1 expression • Macrocyclic azolopyridine derivatives as EED and PRC2 modulators Red Flags HYPE_PRICING ($0.0M rev, $290M mcap) Full assessment →
OPRX OptimizeRx Corporation	6/12	0	CF+	-29.8%	$137.3M	11.5	73	15	23.1%	Health Tech
Score Breakdown Patents: 0/3 • Runway: 3/3 • Revenue: 0/3 • Mgmt: 3/3 Financials Revenue: $98.7M Cash: $24.1M FCF: $15.8M ROE: 3.7% • D/E: 15% Profit Margin: 4.7% Quality FCF+ Low Debt FCF insufficient_data Full assessment →
PMVP PMV Pharmaceuticals, Inc.	6/12	8	13mo	-	$74.8M	-58.5	-	0	9.4%	Biotech
Score Breakdown Patents: 2/3 • Runway: 1/3 • Revenue: 1/3 • Mgmt: 2/3 Financials Revenue: $0.0M Cash: $79.4M FCF: $-43.8M ROE: -70.9% • D/E: 0% Profit Margin: N/A Quality Low Debt FCF insufficient_data Patents (8) • Methods and compounds for restoring mutant p53 function • Deuterated compounds for restoring mutant p53 function • Methods and compounds for restoring mutant p53 function +2 more — view all Full assessment →
OKYO OKYO Pharma Limited	6/12	0	42mo	-	$73.5M	-2.9	-	-	46.8%	Biotech
Score Breakdown Patents: 0/3 • Runway: 2/3 • Revenue: 1/3 • Mgmt: 3/3 Financials Revenue: $0.0M Cash: $20.6M FCF: $-2.1M ROE: -263.8% • D/E: N/A Profit Margin: N/A Quality FCF insufficient_data Full assessment →
BGSF BGSF, Inc.	6/12	0	72mo	-5.1%	$55.0M	25.7	36	1	13.0%	Industrials
Score Breakdown Patents: 0/3 • Runway: 3/3 • Revenue: 0/3 • Mgmt: 3/3 Financials Revenue: $92.1M Cash: $18.2M FCF: $14.1M ROE: -11.2% • D/E: 1% Profit Margin: -9.0% Quality FCF+ Low Debt FCF insufficient_data Full assessment →
IIIN Insteel Industries, Inc.	6/12	0	CF+	+9.9%	$592.6M	-3.0	12	1	4.8%	Industrials
Score Breakdown Patents: 0/3 • Runway: 3/3 • Revenue: 1/3 • Mgmt: 2/3 Financials Revenue: $707.7M Cash: $22.9M FCF: $-17.5M ROE: 10.0% • D/E: 1% Profit Margin: 5.1% Quality Low Debt FCF insufficient_data Full assessment →
VYGR Voyager Therapeutics, Inc.	6/12	23	12mo	-39.1%	$196.6M	-39.3	-237	21	27.8%	Biotech
Score Breakdown Patents: 3/3 • Runway: 0/3 • Revenue: 0/3 • Mgmt: 3/3 Financials Revenue: $34.5M Cash: $116.3M FCF: $-77.3M ROE: -54.1% • D/E: 21% Profit Margin: N/A Quality Low Debt FCF insufficient_data Patents (23) • Compositions and methods for delivery of AAV • Redirection of tropism of AAV capsids • Treatment of amyotrophic lateral sclerosis (ALS) +2 more — view all Full assessment →
SELF Global Self Storage, Inc.	6/12	0	CF+	+0.6%	$58.4M	5.7	60	34	8.2%	Real Estate
Score Breakdown Patents: 0/3 • Runway: 3/3 • Revenue: 1/3 • Mgmt: 2/3 Financials Revenue: $12.8M Cash: $7.5M FCF: $3.3M ROE: 4.5% • D/E: 34% Profit Margin: 16.6% Quality FCF+ Low Debt FCF insufficient_data Full assessment →
NPWR NET Power Inc.	6/12	0	27mo	-	$169.0M	-64.3	-	1	47.7%	Industrial Tech
Score Breakdown Patents: 0/3 • Runway: 2/3 • Revenue: 1/3 • Mgmt: 3/3 Financials Revenue: $0.0M Cash: $308.4M FCF: $-108.6M ROE: -142.0% • D/E: 1% Profit Margin: N/A Quality Low Debt FCF insufficient_data Full assessment →
GRVY GRAVITY Co., Ltd.	6/12	0	CF+	-4.6%	$495.4M	-	32	0	59.3%	Communication Services
Score Breakdown Patents: 0/3 • Runway: 3/3 • Revenue: 0/3 • Mgmt: 3/3 Financials Revenue: $562284.7M Cash: $654692.0M FCF: N/A ROE: 13.2% • D/E: 0% Profit Margin: 15.3% Quality Low Debt FCF insufficient_data Full assessment →
PNRG PrimeEnergy Resources Corporati	6/12	0	CF+	-3.9%	$334.1M	7.2	65	0	63.9%	Energy
Score Breakdown Patents: 0/3 • Runway: 3/3 • Revenue: 0/3 • Mgmt: 3/3 Financials Revenue: $177.7M Cash: $28.7M FCF: $24.0M ROE: 11.7% • D/E: 0% Profit Margin: 14.0% Quality FCF+ Low Debt FCF insufficient_data Full assessment →
GNE Genie Energy Ltd.	6/12	0	CF+	-4.6%	$415.3M	6.0	25	3	17.1%	Utilities
Score Breakdown Patents: 0/3 • Runway: 3/3 • Revenue: 0/3 • Mgmt: 3/3 Financials Revenue: $502.6M Cash: $204.3M FCF: $24.7M ROE: 13.2% • D/E: 3% Profit Margin: 5.0% Quality FCF+ Low Debt FCF insufficient_data Full assessment →
NUCL Eagle Nuclear Energy Corp.	6/12	0	42mo	-	$185.2M	-1.6	-	4	56.7%	Nuclear Energy
Score Breakdown Patents: 0/3 • Runway: 2/3 • Revenue: 1/3 • Mgmt: 3/3 Financials Revenue: $0.0M Cash: $28.1M FCF: $-3.0M ROE: -250.8% • D/E: 4% Profit Margin: N/A Quality Low Debt FCF insufficient_data Full assessment →
PERI Perion Network Ltd	5/12	0	CF+	-4.6%	$379.6M	14.5	34	4	7.6%	Communication Services
Score Breakdown Patents: 0/3 • Runway: 3/3 • Revenue: 0/3 • Mgmt: 2/3 Financials Revenue: $436.2M Cash: $267.8M FCF: $55.1M ROE: -2.0% • D/E: 4% Profit Margin: -3.0% Quality FCF+ Low Debt FCF insufficient_data Full assessment →
HYSR SunHydrogen Inc.	5/12	0	87mo	-	$91.6M	-4.1	100	-	1.2%	Solar Energy
Score Breakdown Patents: 0/3 • Runway: 3/3 • Revenue: 1/3 • Mgmt: 1/3 Financials Revenue: $0.0M Cash: $32.9M FCF: $-3.8M ROE: -15.6% • D/E: N/A Profit Margin: N/A Quality FCF insufficient_data Red Flags SBC_HIGH (82770% of revenue) Full assessment →
LTBR Lightbridge Corporation	5/12	0	168mo	-	$247.4M	-4.2	-	-	5.8%	Electrical Equipment
Score Breakdown Patents: 0/3 • Runway: 3/3 • Revenue: 1/3 • Mgmt: 1/3 Financials Revenue: $0.0M Cash: $237.5M FCF: $-10.4M ROE: -13.9% • D/E: N/A Profit Margin: N/A Quality FCF insufficient_data Red Flags HYPE_PRICING ($0.0M rev, $247M mcap) Full assessment →
GETY Getty Images Holdings, Inc.	5/12	0	24mo	-2.5%	$109.5M	-563.0	72	413	53.2%	Communication Services
Score Breakdown Patents: 0/3 • Runway: 2/3 • Revenue: 0/3 • Mgmt: 3/3 Financials Revenue: $978.0M Cash: $51.6M FCF: $-616.2M ROE: -27.5% • D/E: 413% Profit Margin: -16.2% Quality FCF insufficient_data Full assessment →
LRMR Larimar Therapeutics, Inc.	5/12	7	12mo	-	$407.2M	-23.1	-	4	44.3%	Biotech
Score Breakdown Patents: 2/3 • Runway: 1/3 • Revenue: 1/3 • Mgmt: 1/3 Financials Revenue: $0.0M Cash: $156.3M FCF: $-94.2M ROE: -139.6% • D/E: 4% Profit Margin: N/A Quality Low Debt FCF insufficient_data Patents (7) • Methods for treating myelin associated diseases and mitochondria associated diseases • Pharmaceutical composition comprising frataxin fusion protein and methods of use thereof • Methods for quantifying frataxin activity +2 more — view all Red Flags HYPE_PRICING ($0.0M rev, $407M mcap) Full assessment →
SEER Seer, Inc.	5/12	8	42mo	-23.4%	$108.0M	-24.8	48	10	26.8%	Biotech
Score Breakdown Patents: 2/3 • Runway: 2/3 • Revenue: 0/3 • Mgmt: 1/3 Financials Revenue: $14.2M Cash: $152.9M FCF: $-26.8M ROE: -26.4% • D/E: 10% Profit Margin: N/A Quality Low Debt FCF insufficient_data Patents (8) • Compositions, methods and systems for protein corona analysis and uses thereof • Systems and methods for sample preparation, data generation, and protein corona analysis • Compositions, methods and systems for protein corona analysis and uses thereof +2 more — view all Red Flags SBC_HIGH (173% of revenue) Full assessment →
RCEL Avita Medical, Inc.	5/12	1	6mo	+17.8%	$305.6M	-4.4	82	-	1.5%	Medical Devices
Score Breakdown Patents: 1/3 • Runway: 0/3 • Revenue: 2/3 • Mgmt: 2/3 Financials Revenue: $75.6M Cash: $11.1M FCF: $-13.3M ROE: N/A • D/E: N/A Profit Margin: -57.0% Quality FCF insufficient_data Patents (1) • Tissue processing tray Full assessment →
ASRT Assertio Holdings, Inc.	5/12	0	121mo	-62.5%	$151.9M	5.1	70	53	3.1%	Pharma
Score Breakdown Patents: 0/3 • Runway: 3/3 • Revenue: 0/3 • Mgmt: 2/3 Financials Revenue: $102.2M Cash: $71.6M FCF: $7.8M ROE: -38.8% • D/E: 53% Profit Margin: -34.9% Quality FCF+ FCF insufficient_data Full assessment →
CRBP Corbus Pharmaceuticals Holdings	5/12	0	16mo	-	$157.1M	-31.6	-	4	21.6%	Biotech
Score Breakdown Patents: 0/3 • Runway: 1/3 • Revenue: 1/3 • Mgmt: 3/3 Financials Revenue: $0.0M Cash: $117.9M FCF: $-49.6M ROE: -95.6% • D/E: 4% Profit Margin: N/A Quality Low Debt FCF insufficient_data Full assessment →
TNYA Tenaya Therapeutics, Inc.	5/12	10	18mo	-	$143.5M	-22.7	100	6	5.6%	Biotech
Score Breakdown Patents: 2/3 • Runway: 1/3 • Revenue: 1/3 • Mgmt: 1/3 Financials Revenue: $1.3M Cash: $78.1M FCF: $-32.6M ROE: -121.9% • D/E: 6% Profit Margin: N/A Quality Low Debt FCF insufficient_data Patents (10) • Gene therapy vectors for treating heart disease • Cardiac cell reprogramming with myocardin and ASCL1 • Optimized expression cassettes for gene therapy +2 more — view all Red Flags SBC_HIGH (3804% of revenue) Full assessment →
PRLD Prelude Therapeutics Incorporat	5/12	0	55mo	-	$365.6M	-3.8	100	13	66.0%	Biotech
Score Breakdown Patents: 0/3 • Runway: 3/3 • Revenue: 1/3 • Mgmt: 1/3 Financials Revenue: $22.4M Cash: $151.8M FCF: $-13.8M ROE: -57.7% • D/E: 13% Profit Margin: -269.7% Quality Low Debt FCF insufficient_data Red Flags SBC_HIGH (121% of revenue) Full assessment →
BMEA Biomea Fusion, Inc.	5/12	9	9mo	-	$126.1M	-22.0	-	7	6.7%	Biotech
Score Breakdown Patents: 2/3 • Runway: 0/3 • Revenue: 1/3 • Mgmt: 2/3 Financials Revenue: $0.0M Cash: $34.8M FCF: $-27.8M ROE: -164.1% • D/E: 7% Profit Margin: N/A Quality Low Debt FCF insufficient_data Patents (9) • Inhibitors of menin-mll interaction • Inhibitors of menin-MLL interaction • Pyrazine compounds as inhibitors of FLT3 +2 more — view all Full assessment →
TLSA Tiziana Life Sciences Ltd	5/12	1	4mo	-	$122.2M	-4.5	-	877	51.4%	Biotech
Score Breakdown Patents: 1/3 • Runway: 0/3 • Revenue: 1/3 • Mgmt: 3/3 Financials Revenue: $0.0M Cash: $4.0M FCF: $-5.5M ROE: -924.3% • D/E: 877% Profit Margin: N/A Quality FCF insufficient_data Patents (1) • Dactinomycin compositions and methods for the treatment of myelodysplastic syndrome and acute myeloid leukemia Full assessment →
HNST The Honest Company, Inc.	5/12	0	CF+	-10.9%	$580.4M	12.5	40	6	10.0%	Consumer Defensive
Score Breakdown Patents: 0/3 • Runway: 3/3 • Revenue: 0/3 • Mgmt: 2/3 Financials Revenue: $342.0M Cash: $105.9M FCF: $72.7M ROE: -6.9% • D/E: 6% Profit Margin: -3.6% Quality FCF+ Low Debt FCF insufficient_data Full assessment →
REA Rare Earths Americas, Inc.	5/12	0	60mo	-	$218.7M	-	-	0	59.8%	Basic Materials
Score Breakdown Patents: 0/3 • Runway: 3/3 • Revenue: 1/3 • Mgmt: 1/3 Financials Revenue: $0.0M Cash: $76.7M FCF: N/A ROE: N/A • D/E: 0% Profit Margin: N/A Quality Low Debt FCF insufficient_data Red Flags HYPE_PRICING ($0.0M rev, $219M mcap) Full assessment →
IONR ioneer Ltd	5/12	1	115mo	-	$223.8M	-	100	0	19.8%	Basic Materials
Score Breakdown Patents: 1/3 • Runway: 3/3 • Revenue: 1/3 • Mgmt: 0/3 Financials Revenue: $0.7M Cash: $58.8M FCF: N/A ROE: N/A • D/E: 0% Profit Margin: N/A Quality Low Debt FCF insufficient_data Patents (1) • Apparatus and method for determining parameters of process operation Red Flags SBC_HIGH (305% of revenue) HYPE_PRICING ($0.7M rev, $224M mcap) Full assessment →
IRD Opus Genetics, Inc.	5/12	5	26mo	-73.8%	$502.5M	-7.7	-292	-	22.5%	Biotech
Score Breakdown Patents: 2/3 • Runway: 2/3 • Revenue: 0/3 • Mgmt: 1/3 Financials Revenue: $9.9M Cash: $88.8M FCF: $-38.6M ROE: -4796.5% • D/E: N/A Profit Margin: N/A Quality FCF insufficient_data Patents (5) • Salts and esters of APX3330 and therapeutic uses thereof • Methods and compositions for treatment of mydriasis • Aqueous ophthalmic solutions of phentolamine and medical uses thereof +2 more — view all Red Flags SBC_HIGH (679% of revenue) Full assessment →
CRBU Caribou Biosciences, Inc.	4/12	6	14mo	-43.8%	$136.2M	-43.8	-	27	4.0%	Biotech
Score Breakdown Patents: 2/3 • Runway: 1/3 • Revenue: 0/3 • Mgmt: 1/3 Financials Revenue: $10.0M Cash: $112.3M FCF: $-59.6M ROE: -78.3% • D/E: 27% Profit Margin: N/A Quality Low Debt FCF insufficient_data Patents (6) • Anti-ROR1 antibody and ROR1-targeting engineered cells • Method of capturing CRISPR endonuclease cleavage products • Anti-ROR1 antibody and ROR1-targeting engineered cells +2 more — view all Red Flags SBC_HIGH (76% of revenue) Full assessment →
IPSC Century Therapeutics, Inc.	4/12	3	17mo	-	$351.3M	-14.3	-	17	44.0%	Biotech
Score Breakdown Patents: 1/3 • Runway: 1/3 • Revenue: 1/3 • Mgmt: 1/3 Financials Revenue: $0.0M Cash: $119.7M FCF: $-50.4M ROE: -49.7% • D/E: 17% Profit Margin: N/A Quality Low Debt FCF insufficient_data Patents (3) • Artificial cell death polypeptide for chimeric antigen receptor and uses thereof • Artificial cell death polypeptide for chimeric antigen receptor and uses thereof • Chimeric antigen receptor system with adaptable receptor specificity Red Flags HYPE_PRICING ($0.0M rev, $351M mcap) Full assessment →
VANI Vivani Medical, Inc.	4/12	0	9mo	-	$114.6M	-14.7	-	94	56.9%	Biotech
Score Breakdown Patents: 0/3 • Runway: 0/3 • Revenue: 1/3 • Mgmt: 3/3 Financials Revenue: $0.0M Cash: $19.9M FCF: $-16.8M ROE: -220.4% • D/E: 94% Profit Margin: N/A Quality FCF insufficient_data Full assessment →
VUZI Vuzix Corporation	4/12	33	9mo	-14.1%	$214.4M	-6.7	-10	2	22.7%	Technology
Score Breakdown Patents: 3/3 • Runway: 0/3 • Revenue: 0/3 • Mgmt: 1/3 Financials Revenue: $5.9M Cash: $17.3M FCF: $-14.3M ROE: -94.4% • D/E: 2% Profit Margin: N/A Quality Low Debt FCF insufficient_data Patents (33) • Wearable mobile electronic system • Color correction for virtual images of near-eye displays • Smart glasses +2 more — view all Red Flags SBC_HIGH (136% of revenue) Full assessment →
REKR Rekor Systems, Inc.	4/12	2	11mo	+2.5%	$63.3M	-7.6	58	78	3.5%	Enterprise Software
Score Breakdown Patents: 1/3 • Runway: 0/3 • Revenue: 1/3 • Mgmt: 2/3 Financials Revenue: $49.8M Cash: $9.8M FCF: $-4.8M ROE: -62.8% • D/E: 78% Profit Margin: -43.8% Quality FCF insufficient_data Patents (2) • Systems and methods for efficient information extraction in traffic monitoring • Systems and methods for traffic monitoring with improved privacy protections Full assessment →
MDAI Spectral AI, Inc.	4/12	0	13mo	-30.4%	$51.5M	-12.7	43	-	13.4%	Medical Devices
Score Breakdown Patents: 0/3 • Runway: 1/3 • Revenue: 0/3 • Mgmt: 3/3 Financials Revenue: $15.4M Cash: $14.0M FCF: $-6.6M ROE: N/A • D/E: N/A Profit Margin: -65.5% Quality FCF insufficient_data Full assessment →
REPL Replimune Group, Inc.	4/12	6	8mo	-	$1217.3M	-14.1	-	106	28.2%	Biotech
Score Breakdown Patents: 2/3 • Runway: 0/3 • Revenue: 1/3 • Mgmt: 1/3 Financials Revenue: $0.0M Cash: $195.3M FCF: $-171.7M ROE: -134.3% • D/E: 106% Profit Margin: N/A Quality FCF insufficient_data Patents (6) • Engineered virus • Oncolytic virus strain • Altered virus +2 more — view all Red Flags HYPE_PRICING ($0.0M rev, $1217M mcap) Full assessment →
NKTX Nkarta, Inc.	4/12	3	24mo	-	$208.4M	-26.4	-	30	15.5%	Biotech
Score Breakdown Patents: 1/3 • Runway: 1/3 • Revenue: 1/3 • Mgmt: 1/3 Financials Revenue: $0.0M Cash: $182.8M FCF: $-55.1M ROE: -38.8% • D/E: 30% Profit Margin: N/A Quality Low Debt FCF insufficient_data Patents (3) • Immune cells comprising truncated NKG2D chimeric receptors • Genetically modified natural killer cells for CD70-directed cancer immunotherapy • CD19-directed chimeric antigen receptors and uses thereof in immunotherapy Red Flags HYPE_PRICING ($0.0M rev, $208M mcap) Full assessment →
CNTB Connect Biopharma Holdings Limi	4/12	0	6mo	+5666.7%	$128.5M	-27.0	100	2	66.5%	Biotech
Score Breakdown Patents: 0/3 • Runway: 0/3 • Revenue: 3/3 • Mgmt: 1/3 Financials Revenue: $3.0M Cash: $31.5M FCF: $-34.7M ROE: -140.5% • D/E: 2% Profit Margin: N/A Quality Low Debt FCF insufficient_data Red Flags SBC_HIGH (285% of revenue) Full assessment →
BCYC Bicycle Therapeutics plc	4/12	0	30mo	-78.5%	$269.5M	-37.0	-209	3	0.0%	Biotech
Score Breakdown Patents: 0/3 • Runway: 2/3 • Revenue: 0/3 • Mgmt: 2/3 Financials Revenue: $61.2M Cash: $510.1M FCF: $-99.8M ROE: -32.3% • D/E: 3% Profit Margin: N/A Quality Low Debt FCF insufficient_data Full assessment →
VITL Vital Farms, Inc.	4/12	0	15mo	-10.1%	$418.2M	-23.4	28	38	19.6%	Consumer Defensive
Score Breakdown Patents: 0/3 • Runway: 1/3 • Revenue: 0/3 • Mgmt: 3/3 Financials Revenue: $765.7M Cash: $21.2M FCF: $-98.0M ROE: 0.1% • D/E: 38% Profit Margin: N/A Quality Low Debt FCF insufficient_data Full assessment →
VERI Veritone, Inc.	4/12	6	3mo	+4.6%	$104.5M	-17.3	66	126	10.4%	Enterprise Software
Score Breakdown Patents: 2/3 • Runway: 0/3 • Revenue: 1/3 • Mgmt: 1/3 Financials Revenue: $91.1M Cash: $12.4M FCF: $-18.1M ROE: -547.7% • D/E: 126% Profit Margin: -117.5% Quality FCF insufficient_data Patents (6) • Controlling operation of an electrical grid using reinforcement learning and multi-particle modeling • Cognitive multi-factor authentication • Neural network orchestration +2 more — view all Red Flags SBC_HIGH (63% of revenue) Full assessment →
CGTX Cognition Therapeutics, Inc.	4/12	0	23mo	-	$93.5M	-25.6	-	2	8.1%	Biotech
Score Breakdown Patents: 0/3 • Runway: 1/3 • Revenue: 1/3 • Mgmt: 2/3 Financials Revenue: $0.0M Cash: $34.0M FCF: $-24.0M ROE: -83.8% • D/E: 2% Profit Margin: N/A Quality Low Debt FCF insufficient_data Full assessment →
DAVA Endava plc	4/12	0	CF+	-8.4%	$153.8M	20.1	22	138	10.5%	Enterprise Software
Score Breakdown Patents: 0/3 • Runway: 3/3 • Revenue: 0/3 • Mgmt: 1/3 Financials Revenue: $727.6M Cash: $48.4M FCF: $30.9M ROE: -99.8% • D/E: 138% Profit Margin: -56.1% Quality FCF+ FCF insufficient_data Red Flags SBC_HIGH (61% of revenue) Full assessment →
SWMR Swarmer, Inc	4/12	0	21mo	+56.6%	$630.9M	-	49	1	94.5%	Enterprise Software
Score Breakdown Patents: 0/3 • Runway: 1/3 • Revenue: 3/3 • Mgmt: 0/3 Financials Revenue: $0.3M Cash: $25.3M FCF: N/A ROE: N/A • D/E: 1% Profit Margin: N/A Quality Low Debt FCF insufficient_data Red Flags SBC_HIGH (1230% of revenue) HYPE_PRICING ($0.3M rev, $631M mcap) Full assessment →
NNOX NANO-X IMAGING LTD	3/12	0	8mo	+36.7%	$56.9M	-54.1	-77	11	18.0%	Medical Devices
Score Breakdown Patents: 0/3 • Runway: 0/3 • Revenue: 2/3 • Mgmt: 1/3 Financials Revenue: $15.6M Cash: $31.0M FCF: $-30.8M ROE: -99.0% • D/E: 11% Profit Margin: N/A Quality Low Debt FCF insufficient_data Red Flags SBC_HIGH (448% of revenue) Full assessment →
STXS Stereotaxis, Inc.	3/12	0	8mo	-12.8%	$129.3M	-6.8	56	30	34.6%	Medical Devices
Score Breakdown Patents: 0/3 • Runway: 0/3 • Revenue: 0/3 • Mgmt: 3/3 Financials Revenue: $30.1M Cash: $10.5M FCF: $-8.8M ROE: -184.3% • D/E: 30% Profit Margin: -74.2% Quality Low Debt FCF insufficient_data Full assessment →
ABOS Acumen Pharmaceuticals, Inc.	3/12	0	14mo	-	$211.2M	-26.8	-	55	48.8%	Biotech
Score Breakdown Patents: 0/3 • Runway: 1/3 • Revenue: 1/3 • Mgmt: 1/3 Financials Revenue: $0.0M Cash: $110.2M FCF: $-56.5M ROE: -120.5% • D/E: 55% Profit Margin: N/A Quality FCF insufficient_data Red Flags HYPE_PRICING ($0.0M rev, $211M mcap) Full assessment →
ZNTL Zentalis Pharmaceuticals, Inc.	3/12	0	16mo	-	$332.3M	-23.9	-	26	39.8%	Biotech
Score Breakdown Patents: 0/3 • Runway: 1/3 • Revenue: 1/3 • Mgmt: 1/3 Financials Revenue: $0.0M Cash: $174.6M FCF: $-79.5M ROE: -66.7% • D/E: 26% Profit Margin: N/A Quality Low Debt FCF insufficient_data Red Flags HYPE_PRICING ($0.0M rev, $332M mcap) Full assessment →
RCKT Rocket Pharmaceuticals, Inc.	3/12	0	20mo	-	$367.7M	23.4	-	7	20.3%	Biotech
Score Breakdown Patents: 0/3 • Runway: 1/3 • Revenue: 1/3 • Mgmt: 1/3 Financials Revenue: $0.0M Cash: $283.7M FCF: $86.1M ROE: -4.8% • D/E: 7% Profit Margin: N/A Quality FCF+ Low Debt FCF insufficient_data Red Flags HYPE_PRICING ($0.0M rev, $368M mcap) Full assessment →
GANX Gain Therapeutics, Inc.	3/12	0	8mo	-	$76.4M	-14.6	-	5	2.3%	Biotech
Score Breakdown Patents: 0/3 • Runway: 0/3 • Revenue: 1/3 • Mgmt: 2/3 Financials Revenue: $0.0M Cash: $13.1M FCF: $-11.1M ROE: -268.3% • D/E: 5% Profit Margin: N/A Quality Low Debt FCF insufficient_data Full assessment →
CRDF Cardiff Oncology, Inc.	3/12	3	10mo	-14.1%	$94.1M	-25.8	-	2	3.1%	Biotech
Score Breakdown Patents: 1/3 • Runway: 0/3 • Revenue: 0/3 • Mgmt: 2/3 Financials Revenue: $0.5M Cash: $34.5M FCF: $-24.3M ROE: -94.1% • D/E: 2% Profit Margin: N/A Quality Low Debt FCF insufficient_data Patents (3) • PLK1 inhibitor in combination with anti-angiogenics for treating metastatic cancer • PLK1 inhibitor in combination with anti-angiogenics for treating metastatic cancer • Cancer treatment using FGFR inhibitors and PLK1 inhibitors Full assessment →
DMAC DiaMedica Therapeutics Inc.	3/12	0	17mo	-	$348.9M	-5.1	-	0	53.1%	Biotech
Score Breakdown Patents: 0/3 • Runway: 1/3 • Revenue: 1/3 • Mgmt: 1/3 Financials Revenue: $0.0M Cash: $43.5M FCF: $-17.6M ROE: -114.6% • D/E: 0% Profit Margin: N/A Quality Low Debt FCF insufficient_data Red Flags HYPE_PRICING ($0.0M rev, $349M mcap) Full assessment →
CBUS Cibus, Inc.	3/12	1	5mo	+6.5%	$120.0M	-43.7	100	1934	25.1%	Biotech
Score Breakdown Patents: 1/3 • Runway: 0/3 • Revenue: 1/3 • Mgmt: 1/3 Financials Revenue: $4.3M Cash: $20.4M FCF: $-52.5M ROE: -223.2% • D/E: 1934% Profit Margin: N/A Quality FCF insufficient_data Patents (1) • Plant shade Red Flags SBC_HIGH (1199% of revenue) Full assessment →
UPB Upstream Bio, Inc.	3/12	3	23mo	-17.5%	$313.8M	-27.6	100	0	21.8%	Biotech
Score Breakdown Patents: 1/3 • Runway: 1/3 • Revenue: 0/3 • Mgmt: 1/3 Financials Revenue: $3.2M Cash: $261.3M FCF: $-86.6M ROE: -46.1% • D/E: 0% Profit Margin: N/A Quality Low Debt FCF insufficient_data Patents (3) • Pharmaceutical composition comprising anti-human TSLP receptor antibody • Pharmaceutical compositions comprising anti-human TSLP receptor antibodies and methods of using the same • Pharmaceutical composition comprising anti-human TSLP receptor antibody Red Flags SBC_HIGH (638% of revenue) Full assessment →
NINE Nine Energy Service, Inc.	3/12	0	8mo	-3.7%	$146.6M	-2.4	14	100	34.8%	Energy Services
Score Breakdown Patents: 0/3 • Runway: 0/3 • Revenue: 0/3 • Mgmt: 3/3 Financials Revenue: $536.0M Cash: $16.8M FCF: $-3.6M ROE: 283.8% • D/E: 100% Profit Margin: 12.7% Quality High ROE FCF insufficient_data Full assessment →
BTQ BTQ Technologies Corp.	3/12	1	5mo	-	$416.2M	-0.7	-	6	35.0%	Enterprise Software
Score Breakdown Patents: 1/3 • Runway: 0/3 • Revenue: 1/3 • Mgmt: 1/3 Financials Revenue: $0.0M Cash: $9.8M FCF: $-3.0M ROE: -489.2% • D/E: 6% Profit Margin: N/A Quality Low Debt FCF insufficient_data Patents (1) • Non-volatile storage of secure data in 6T SRAM cells using hot carrier injection Red Flags HYPE_PRICING ($0.0M rev, $416M mcap) Full assessment →
GALT Galectin Therapeutics Inc.	2/12	0	10mo	-	$394.3M	-3.8	-	-	52.6%	Biotech
Score Breakdown Patents: 0/3 • Runway: 0/3 • Revenue: 1/3 • Mgmt: 1/3 Financials Revenue: $0.0M Cash: $13.3M FCF: $-14.9M ROE: N/A • D/E: N/A Profit Margin: N/A Quality FCF insufficient_data Red Flags HYPE_PRICING ($0.0M rev, $394M mcap) Full assessment →
ADUR Aduro Clean Technologies Inc.	2/12	0	47mo	-100.0%	$457.2M	-1.8	100	2	31.7%	Industrials
Score Breakdown Patents: 0/3 • Runway: 2/3 • Revenue: 0/3 • Mgmt: 0/3 Financials Revenue: $0.2M Cash: $38.4M FCF: $-8.2M ROE: -128.9% • D/E: 2% Profit Margin: N/A Quality Low Debt FCF insufficient_data Red Flags SBC_HIGH (10163% of revenue) HYPE_PRICING ($0.2M rev, $457M mcap) Full assessment →
GCTS GCT Semiconductor Holding, Inc.	1/12	0	10mo	-17.9%	$175.7M	-15.3	-38	-	11.3%	Semiconductors
Score Breakdown Patents: 0/3 • Runway: 0/3 • Revenue: 0/3 • Mgmt: 1/3 Financials Revenue: $4.1M Cash: $30.2M FCF: $-26.9M ROE: N/A • D/E: N/A Profit Margin: N/A Quality FCF insufficient_data Red Flags SBC_HIGH (369% of revenue) Full assessment →

39 stocks auto-rejected (red flags)

MCRB reverse_split

EVTL reverse_split

ARQQ reverse_split

SPCE reverse_split

VELO reverse_split

LIDR reverse_split

MVIS reverse_split

WATT reverse_split

ACET reverse_split

KULR reverse_split

ALIT reverse_split

SENS reverse_split

NRXP reverse_split

AGEN reverse_split

DTIL reverse_split

GOSS reverse_split

RIGL reverse_split

PYPD reverse_split

LYEL reverse_split

MNPR reverse_split

SABS reverse_split

BNED reverse_split

XFOR reverse_split

COOK reverse_split

DPRO reverse_split

YSG reverse_split

GDEV reverse_split

NRDY reverse_split

VIVO reverse_split

FBIO reverse_split

BNAI reverse_split

SRZN reverse_split

IBIO reverse_split

TNXP reverse_split

DVLT reverse_split

NGNE reverse_split

ASMB reverse_split

GRRR reverse_split

SIDU reverse_split

Disclaimer: Micro cap stocks are inherently risky. This screener identifies innovation signals — it is not a buy recommendation. Always do your own due diligence. See our 7-step risk assessment methodology and full disclaimer.